Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestiv

Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestiv

Item

http://www.wikidata.org/entity/Q34665199

Q34665199

about

Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma Current and emerging therapies in unresectable and recurrent gastric cancer Advanced gastric cancer: Current treatment landscape and future perspectives Novel targets in the treatment of advanced gastric cancer: a perspective review Second-line treatment of metastatic gastric cancer: Current options and future directions Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma Construction of quality of life change patterns: example in oncology in a phase III therapeutic trial (FFCD 0307)Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth.Downregulation of Sp1 by Minnelide leads to decrease in HSP70 and decrease in tumor burden of gastric cancer Seom guidelines for the treatment of gastric cancer 2015.Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma.Report from the 17th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Edmonton, Alberta; 11-12 September 2015.Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).Chemotherapy for advanced gastric cancer.Capecitabine for the treatment of gastric cancer.Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer.Current advances in targeted therapies for metastatic gastric cancer: improving patient care.Esophageal Cancer: New Insights into a Heterogenous Disease.Esophagogastric Adenocarcinoma: Is More Chemotherapy Better?A Bayesian network meta-analysis on second-line systemic therapy in advanced gastric cancer.Evolving treatments for advanced gastric cancer: appraisal of the survival trend.Unintentional Long-Term Esophageal Stenting due to a Complete Response in a Patient with Stage UICC IV Adenocarcinoma of the Gastroesophageal Junction.Perioperative chemotherapy versus postoperative chemoradiotherapy in patients with resectable gastric/gastroesophageal junction adenocarcinomas: A survival analysis of 5058 patients.The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.An update in the nonendoscopic treatment of gastric cancer.Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.Advanced gastric adenocarcinoma: optimizing therapy options.Survival after failure of first-line chemotherapy in advanced gastric cancer patients: differences between Japan and the rest of the world.A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO).Tumor regression grade in gastric cancer: Predictors and impact on outcome.Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting-Practice and Outcomes.Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.Gastric Adenocarcinoma: A Multimodal Approach.Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy.Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study.Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer.Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study.

P2860

Q26741530-2DA08694-AE4C-4DC6-A0A6-25DEE9990B00 Q26745453-397C3840-04A3-4CCB-9936-8B1E639CF166 Q26764934-C242FD92-A6F5-4862-BE96-52CDB01241CB Q26765208-0857C79C-6614-4A49-846D-965B61CB293B Q26778027-F262BC34-04E0-4A75-B085-CBB6EE31FF8C Q26798400-24063500-C3BD-442A-BD81-541293128FE5 Q28077666-ECAE7A00-D022-40AD-B2E5-7C9E39387C28 Q28079750-9E9DF0EE-FCDE-49DB-8AA0-9CEFD8AF6242 Q36082095-6B1BFDF0-7E99-4229-9FCA-A9A9BB40EBE9 Q36253212-14A22870-A5E2-4976-BDC4-B223110A4982 Q36278712-708F94B3-DB91-447A-9656-7951B1CFA215 Q36400378-CE24CF16-688B-4DA9-8459-AEDECF32F51D Q37362948-3C311E76-3D28-4697-91D2-2EBE39E01B66 Q37400172-13DCA269-231E-4C95-AA00-B6AF948E5FC5 Q37524936-204CBCEA-2790-4FCC-BB6E-5921EC148B2B Q37689109-87E15E2D-69EA-4C6F-B079-2374D6A2F4BE Q38604012-884DD299-0B40-4C47-83D2-4621A8C0F499 Q38608072-AD45964B-1D71-4662-A891-26B3D687FD23 Q38613413-8B272FEE-9B52-4576-8D7D-E6F8FDF0FDC5 Q38720829-93A4B49F-6B09-4CF2-8087-41F1461EE9EF Q38734003-A51A30E4-9E3D-471B-A839-038B8714CB6B Q38794776-27CB4A6F-CDF1-41FE-9C23-E426DC0B2C80 Q38813151-AFECF2A5-083D-4176-BE42-C8E62EDDC6E1 Q38823374-D20C5F85-07E2-4F9B-9053-CCA2E49263C6 Q38837448-CB57E2CA-FE25-4ACF-9591-1B08D1703A13 Q38848598-3112968F-10C8-44C9-B27A-ABF4CE49DDC1 Q38941416-381A8C62-8A48-4A9E-B18D-8AEE5B5A3926 Q38956298-93D39599-A1EE-4750-9810-02967E2C15F0 Q38956434-2B1F7BEC-D0C9-4328-9B3A-669AED7EB79C Q39091817-DD989990-5A6A-4E95-9585-1D82DCF876DC Q39234296-3FDE3472-0041-4A27-BA85-49EB614FCE04 Q40377448-B2515E43-84D0-4E13-A388-B25E218F598C Q40744902-105CA942-4DCF-4B0F-83A1-6292663D67ED Q41037588-FC5E72C5-DFAD-46FC-8545-804669C280E0 Q41187621-D72F5F74-C941-451C-BCAC-9CBA8782FF7C Q41221377-D6851ACF-B505-480E-9530-DA2EF0207571 Q41383019-A223A9BC-ADAF-4A83-B94A-E1B7B20EB784 Q47100522-5433AB91-D486-4047-A156-8D7E40828E45 Q47139613-BE2785BB-3CA8-4B51-AF76-6599D5FC3861 Q47678852-DC51EC96-3C90-4E12-88F7-88C78B060C9E

P2860

Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestiv

Item

http://www.wikidata.org/entity/Q34665199

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu